OCON Healthcare has signed an exclusive licensing agreement with BioGenuine to market its products in China and Southeast Asian countries

OCON Healthcare, the Israeli FEMTECH company, which develops, manufactures, and markets a unique and innovative platform for the delivery of drugs to the uterus reports that it has signed an exclusive licensing agreement with BioGenuine, a Chinese pharmaceutical company in the field of Women's Health, which will begin marketing OCON’s products (IUB™ Ballerine® and IUB™ SEAD™) exclusively in China and Southeast Asia. It is also stipulated that the companies will work for the joint development and commercialization of new products in the field of women's health based on OCON's spherical platform combined with innovative drugs.

“We are proud to be at the forefront of change by bringing OCON’s next-generation, 3-dimensional, spherical IUB platform to Chinese women and offering them less invasive and safer choices. Through our exclusive partnership with OCON, we are able to position BioGenuine as a pioneer in advancing women’s health and their quality of life in China.” Baohua Ji, CEO BioGenuine.

OCON's first platform product, the IUB™ Ballerine® is the first and only 3D spherical intrauterine device in the world to prevent pregnancy, that has already proven safety and efficacy in the European, Israeli, and South African markets and will soon enter the South American and Canadian markets. The IUB™ is an ideal delivery platform for treatments for a variety of uterine disorders, such as increased bleeding, endometriosis, fibroids, menopause, and more.

OCON's second product, currently in a Phase IIb clinical trial in Israel and Georgia, is the IUB™ SEAD™ – intended for non-invasive treatment of Heavy Menstrual Bleeding (HMB), from which 1 in 4 women of childbearing age suffers. The treatment is performed in the doctor's clinic within less than 30 minutes without the need for surgery or anesthesia and is designed to lead to a significant and immediate reduction in bleeding. OCON's treatment is a paradigm shift compared to the traditional HMB treatments currently available in hospitals, which include invasive ablation procedures and even hysterectomy. OCON Healthcare estimates that the global HMB surgery market is expected to reach $ 1.3 billion by 2024.

OCON has recently begun developing a new product, IUB™ PRIMA™, which will enable the sustained release of a variety of drugs in the uterus over a fixed and defined period of time to target therapy areas such as endometriosis (1 in 10 women), myomas / uterine fibroids (7 to 8 in 10 women), heavy menstrual bleeding (1 in 4 women) and other areas like menopause - delivered directly through the uterus moving away from systemic side effects.